Experts in the field of eczema, including myself, have long been frustrated by the fact that new and effective treatments for the condition were not being developed. For many years, the only options our patients have had were steroids. This does not make our job easy, as steroids are often viewed with mistrust
However, there is a new topical treatment for eczema on the horizon: Crisaborole. A non-steroidal cream has passed all the FDA safety requirements, and it’s looking like a great alternative to the options currently available.
“This is a fairly rapidly effective treatment,” explained Dr. Mark G. Lebwohl, who presented the findings at the annual congress of the European Academy of Dermatology and Venereology. “It has a favorable safety profile and has been studied in patients as young as 2 years of age. It may represent a new, safe, and efficacious treatment for patients 2 years of age and older with mild to moderate atopic dermatitis.”
Dr. Lebwohl also elaborated on what makes crisaborole different: the answer lies in its most essential element, boron. Boron stimulates chemical levels in the body that result in a steep reduction of inflammatory proteins.
Currently, the company Anacor is developing the drug to treat eczema as well as other diseases. Given that it is still in the early stages, it will probably take another 2-3 years before it is accessible to patients. Nevertheless, it’s incredibly exciting to see something new being published about a topical treatment for the first time in a long time, and I’m looking forward to seeing this on the market.